Lenacapavir: an attractive option, but proceed with caution
Lancet HIV
.
2023 Aug;10(8):e486-e487.
doi: 10.1016/S2352-3018(23)00170-4.
Epub 2023 Jul 11.
Author
Marianne Harris
1
Affiliation
1
British Columbia Centre for Excellence in HIV/AIDS and Department of Family Practice, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: mharris@bccfe.ca.
PMID:
37451298
DOI:
10.1016/S2352-3018(23)00170-4
No abstract available
Publication types
Comment
MeSH terms
Anti-HIV Agents* / adverse effects
HIV Infections* / drug therapy
Humans
Substances
Anti-HIV Agents